Comparative Pharmacology
Head-to-head clinical analysis: CANTIL versus LIBRAX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CANTIL versus LIBRAX.
CANTIL vs LIBRAX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CANTIL (mepenzolate bromide) is a quaternary ammonium anticholinergic agent that blocks muscarinic acetylcholine receptors, reducing gastrointestinal motility and gastric acid secretion.
Chlordiazepoxide is a benzodiazepine that enhances GABA-A receptor activity, increasing chloride ion conductance and causing CNS depression. Clidinium is an anticholinergic that blocks muscarinic acetylcholine receptors, reducing gastrointestinal motility and secretions.
50 mg orally three times daily, may increase to 100 mg three times daily if needed
1-2 capsules orally 3-4 times daily (each capsule contains chlordiazepoxide 5 mg and clidinium 2.5 mg).
None Documented
None Documented
Terminal elimination half-life is approximately 10-12 hours; clinically, this supports twice-daily dosing in patients with normal renal function.
Chlordiazepoxide: 5-30 hours (terminal half-life; increases with age, liver disease; active metabolite desmethyldiazepam has half-life 30-200 hours). Clidinium: 3-4 hours.
Primarily renal excretion of unchanged drug and metabolites; approximately 60-70% eliminated renally, with about 30-40% excreted in feces via biliary elimination.
Chlordiazepoxide (CDX): Renal (1-2% unchanged, 4-6% as metabolites), biliary/fecal (minor). Clidinium bromide: Fecal (50-60% as unchanged drug), renal (40-50% as metabolites and unchanged).
Category C
Category C
Anticholinergic / Antispasmodic
Antispasmodic